Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.
Arndt A, Neumann C, Riecke A, Bauer A, Müller M, Wölfle-Guter M, Grunert M, Busch H, Künstner A, von Bubnoff N, Fliedner S, Greinert D, Osius J, Nagarathinam K, Steinestel K, Gorantla SP, Gebauer N, Witte HM.
Arndt A, et al.
Oncologist. 2024 Jul 3:oyae143. doi: 10.1093/oncolo/oyae143. Online ahead of print.
Oncologist. 2024.
PMID: 38960389
Free article.